Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Revenue of Sio Gene Therapies Inc. (SIOX)
Revenue in 2022 (TTM): $
According to Sio Gene Therapies Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Sio Gene Therapies Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $ | $-70,935,000 | $-71,628,000 | $-71,887,000 |
| 2021 | $ | $ | $-29,372,000 | $-32,637,000 | $-32,425,000 |
| 2020 | $ | $ | $ | $-72,190,000 | $-72,628,000 |
| 2019 | $ | $ | $-121,402,000 | $-128,932,000 | $-129,065,000 |
| 2018 | $ | $ | $-210,024,000 | $-220,652,000 | $-221,573,000 |
| 2017 | $ | $ | $-179,476,000 | $-182,011,000 | $-180,951,000 |
| 2016 | $ | $ | $ | $-133,162,000 | $-133,145,000 |
| 2015 | $ | $ | $ | $ | $ |